CL2020002387A1 - Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123) - Google Patents
Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123)Info
- Publication number
- CL2020002387A1 CL2020002387A1 CL2020002387A CL2020002387A CL2020002387A1 CL 2020002387 A1 CL2020002387 A1 CL 2020002387A1 CL 2020002387 A CL2020002387 A CL 2020002387A CL 2020002387 A CL2020002387 A CL 2020002387A CL 2020002387 A1 CL2020002387 A1 CL 2020002387A1
- Authority
- CL
- Chile
- Prior art keywords
- peptides
- seq
- combination
- cancer
- immunotherapy against
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001118—Receptors for colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invención se refiere a péptidos (SEQ ID NO: 39), proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633325P | 2018-02-21 | 2018-02-21 | |
DE102018103944 | 2018-02-21 | ||
DE102018107224.4A DE102018107224A1 (de) | 2018-02-21 | 2018-03-27 | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002387A1 true CL2020002387A1 (es) | 2021-02-12 |
Family
ID=67482070
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002123A CL2020002123A1 (es) | 2018-02-21 | 2020-08-18 | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. |
CL2020002387A CL2020002387A1 (es) | 2018-02-21 | 2020-09-15 | Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123) |
CL2021000842A CL2021000842A1 (es) | 2018-02-21 | 2021-04-05 | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) |
CL2021000841A CL2021000841A1 (es) | 2018-02-21 | 2021-04-05 | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002123A CL2020002123A1 (es) | 2018-02-21 | 2020-08-18 | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000842A CL2021000842A1 (es) | 2018-02-21 | 2021-04-05 | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) |
CL2021000841A CL2021000841A1 (es) | 2018-02-21 | 2021-04-05 | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) |
Country Status (21)
Country | Link |
---|---|
US (79) | US10993962B2 (es) |
EP (2) | EP3755708A1 (es) |
JP (2) | JP2021514178A (es) |
KR (2) | KR20200116527A (es) |
CN (1) | CN114040921A (es) |
AU (5) | AU2019225879B2 (es) |
BR (2) | BR112020014272A2 (es) |
CA (1) | CA3086916A1 (es) |
CL (4) | CL2020002123A1 (es) |
CO (1) | CO2020009869A2 (es) |
CR (1) | CR20200365A (es) |
DE (1) | DE102018107224A1 (es) |
EA (2) | EA202091833A1 (es) |
IL (2) | IL276845A (es) |
MA (1) | MA51890A (es) |
MX (2) | MX2020007767A (es) |
PE (2) | PE20211300A1 (es) |
PH (1) | PH12020551295A1 (es) |
SG (2) | SG11202006630RA (es) |
TW (2) | TWI776160B (es) |
WO (1) | WO2019162110A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
EP3976805A1 (en) | 2019-05-27 | 2022-04-06 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
MX2021015033A (es) | 2019-06-06 | 2022-01-18 | Immatics Biotechnologies Gmbh | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. |
US20230239852A1 (en) * | 2020-10-16 | 2023-07-27 | Apple Inc. | System and method for fast beam tracking in a high frequency wireless communication system |
DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
WO2023039673A1 (en) * | 2021-09-17 | 2023-03-23 | Université de Montréal | Novel tumor-specific antigens for colorectal cancer and uses thereof |
WO2023144231A1 (en) | 2022-01-25 | 2023-08-03 | Ervaccine Technologies | New method for identifying herv-derived epitopes |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
DD147855A5 (de) | 1978-12-22 | 1981-04-22 | Biogen Nv | Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
ES2138662T3 (es) | 1993-06-03 | 2000-01-16 | Therapeutic Antibodies Inc | Produccion de fragmentos de anticuerpos. |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US5759812A (en) | 1996-11-15 | 1998-06-02 | Incyte Pharmaceuticals, Inc. | Human selenium-binding protein |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO2000013699A1 (en) | 1998-09-04 | 2000-03-16 | Ludwig Institute For Cancer Research | An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor |
EP1001022A1 (en) | 1998-10-16 | 2000-05-17 | Boehringer Ingelheim International GmbH | CAMEL, an alternative translation product of the tumour antigen LAGE-1 |
US7504490B1 (en) | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
ATE332366T1 (de) * | 1999-09-10 | 2006-07-15 | Univ Sydney | Dipeptidyl-peptidasen |
ATE472601T1 (de) | 2000-03-27 | 2010-07-15 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
AU7524601A (en) | 2000-06-05 | 2001-12-17 | Sunol Molecular Corp | T cell receptor fusions and conjugates and methods of use thereof |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
US20030223994A1 (en) | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
JP4436319B2 (ja) | 2002-10-09 | 2010-03-24 | メディジーン リミテッド | 単鎖組換えt細胞レセプター |
NZ539226A (en) | 2002-11-09 | 2008-09-26 | Medigene Ltd | T cell receptor display |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
DE102005041616B4 (de) * | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
DK1760088T3 (da) | 2005-09-05 | 2008-06-09 | Immatics Biotechnologies Gmbh | Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler |
WO2008039974A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
PT2113253E (pt) | 2008-04-30 | 2010-06-15 | Immatics Biotechnologies Gmbh | Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas |
HUE024541T2 (hu) | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
BR112013010213A2 (pt) | 2010-10-26 | 2019-09-24 | Technion Research & Development Foundation Ltd | anticorpos que unem ligantes solúveis de receptores de célula t |
WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
EP2935325B1 (en) | 2012-12-21 | 2018-02-07 | Technische Universität Dresden | Inhibitors of hairy and split 3 (hes3) as a new anti-cancer strategy |
EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
TWI777195B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(三) |
GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
CN108513593A (zh) * | 2015-04-23 | 2018-09-07 | 南托米克斯有限责任公司 | 癌症新表位 |
GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
GB201520579D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
JP7382310B2 (ja) * | 2017-09-06 | 2023-11-16 | カリフォルニア インスティチュート オブ テクノロジー | シグナリング及び抗原提示の2機能性レセプター(sabr) |
FR3070845B1 (fr) | 2017-09-13 | 2021-07-30 | Oreal | Outil de mesure d'au moins une propriete d'une surface corporelle et procede de mesure associe |
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
-
2018
- 2018-03-27 DE DE102018107224.4A patent/DE102018107224A1/de not_active Withdrawn
-
2019
- 2019-02-08 SG SG11202006630RA patent/SG11202006630RA/en unknown
- 2019-02-08 CN CN201980013690.5A patent/CN114040921A/zh active Pending
- 2019-02-08 JP JP2020536952A patent/JP2021514178A/ja active Pending
- 2019-02-08 KR KR1020207027250A patent/KR20200116527A/ko active Application Filing
- 2019-02-08 BR BR112020014272-7A patent/BR112020014272A2/pt unknown
- 2019-02-08 AU AU2019225879A patent/AU2019225879B2/en active Active
- 2019-02-08 EA EA202091833A patent/EA202091833A1/ru unknown
- 2019-02-08 EP EP19704315.1A patent/EP3755708A1/en active Pending
- 2019-02-08 PE PE2020001911A patent/PE20211300A1/es unknown
- 2019-02-08 MA MA051890A patent/MA51890A/fr unknown
- 2019-02-08 EP EP23216383.2A patent/EP4321529A2/en active Pending
- 2019-02-08 CA CA3086916A patent/CA3086916A1/en active Pending
- 2019-02-08 SG SG10202010171VA patent/SG10202010171VA/en unknown
- 2019-02-08 MX MX2020007767A patent/MX2020007767A/es unknown
- 2019-02-08 EA EA202091754A patent/EA202091754A1/ru unknown
- 2019-02-08 KR KR1020207024053A patent/KR20200123134A/ko active Search and Examination
- 2019-02-08 BR BR122020014377A patent/BR122020014377A8/pt unknown
- 2019-02-08 CR CR20200365A patent/CR20200365A/es unknown
- 2019-02-08 PE PE2020001251A patent/PE20210376A1/es unknown
- 2019-02-08 WO PCT/EP2019/053168 patent/WO2019162110A1/en active Application Filing
- 2019-02-13 US US16/274,505 patent/US10993962B2/en active Active
- 2019-02-21 TW TW109118042A patent/TWI776160B/zh active
- 2019-02-21 TW TW108105788A patent/TW201936630A/zh unknown
- 2019-04-05 US US16/376,727 patent/US11077142B2/en active Active
- 2019-04-05 US US16/376,676 patent/US10894064B2/en active Active
- 2019-04-05 US US16/376,663 patent/US11033583B2/en active Active
- 2019-10-21 US US16/659,347 patent/US10695375B2/en active Active
- 2019-10-21 US US16/659,291 patent/US10695374B2/en active Active
- 2019-10-21 US US16/659,256 patent/US10695373B2/en active Active
- 2019-11-22 US US16/692,035 patent/US10695376B2/en active Active
- 2019-11-22 US US16/692,108 patent/US10695377B2/en active Active
- 2019-12-04 US US16/703,034 patent/US10702553B2/en active Active
- 2019-12-04 US US16/703,061 patent/US10709736B2/en active Active
-
2020
- 2020-02-05 US US16/782,620 patent/US10709738B2/en active Active
- 2020-02-05 US US16/782,648 patent/US10772915B2/en active Active
- 2020-02-05 US US16/782,252 patent/US10709737B2/en active Active
- 2020-02-13 US US16/790,062 patent/US10813953B2/en active Active
- 2020-02-14 US US16/791,591 patent/US10792307B2/en active Active
- 2020-02-14 US US16/791,552 patent/US10799537B2/en active Active
- 2020-02-14 US US16/791,598 patent/US10751369B2/en active Active
- 2020-03-10 US US16/814,508 patent/US10888582B2/en active Active
- 2020-03-27 US US16/833,146 patent/US10780123B2/en active Active
- 2020-03-27 US US16/833,175 patent/US10780124B2/en active Active
- 2020-03-27 US US16/833,110 patent/US10780122B2/en active Active
- 2020-03-27 US US16/833,187 patent/US10792308B2/en active Active
- 2020-03-27 US US16/833,162 patent/US10888583B2/en active Active
- 2020-05-01 US US16/864,929 patent/US10874695B2/en active Active
- 2020-05-06 US US16/867,823 patent/US10905719B2/en active Active
- 2020-05-06 US US16/867,844 patent/US11013766B2/en active Active
- 2020-05-11 US US16/871,156 patent/US10869890B2/en active Active
- 2020-05-11 US US16/871,173 patent/US10869891B2/en active Active
- 2020-05-22 US US16/881,572 patent/US10869893B2/en active Active
- 2020-05-22 US US16/881,547 patent/US10869892B2/en active Active
- 2020-05-22 US US16/881,758 patent/US10869894B2/en active Active
- 2020-05-22 US US16/881,795 patent/US10874696B2/en active Active
- 2020-06-12 US US16/900,430 patent/US10888586B2/en active Active
- 2020-06-12 US US16/900,334 patent/US10869895B2/en active Active
- 2020-06-12 US US16/900,401 patent/US10888584B2/en active Active
- 2020-06-12 US US16/900,417 patent/US10888585B2/en active Active
- 2020-06-12 US US16/900,360 patent/US10869896B2/en active Active
- 2020-06-26 US US16/914,088 patent/US10898519B2/en active Active
- 2020-06-26 US US16/914,073 patent/US11020433B2/en active Active
- 2020-06-26 US US16/914,135 patent/US11033585B2/en active Active
- 2020-06-26 US US16/914,059 patent/US10898518B2/en active Active
- 2020-06-30 US US16/917,263 patent/US11020434B2/en active Active
- 2020-06-30 US US16/917,211 patent/US10905720B2/en active Active
- 2020-07-08 AU AU2020204568A patent/AU2020204568B2/en active Active
- 2020-07-22 MX MX2020007808A patent/MX2020007808A/es unknown
- 2020-08-11 CO CONC2020/0009869A patent/CO2020009869A2/es unknown
- 2020-08-18 CL CL2020002123A patent/CL2020002123A1/es unknown
- 2020-08-20 IL IL276845A patent/IL276845A/en unknown
- 2020-08-20 PH PH12020551295A patent/PH12020551295A1/en unknown
- 2020-08-27 IL IL276987A patent/IL276987A/en unknown
- 2020-09-15 CL CL2020002387A patent/CL2020002387A1/es unknown
- 2020-11-04 US US17/089,499 patent/US11040069B2/en active Active
- 2020-11-04 US US17/089,279 patent/US10993964B2/en active Active
- 2020-11-04 US US17/089,486 patent/US11026977B2/en active Active
- 2020-11-04 US US17/089,353 patent/US11013769B2/en active Active
- 2020-11-04 US US17/089,502 patent/US11052113B2/en active Active
- 2020-11-04 US US17/089,330 patent/US11013768B2/en active Active
- 2020-11-13 US US17/097,692 patent/US11052114B2/en active Active
- 2020-11-13 US US17/097,798 patent/US11065279B2/en active Active
- 2020-12-10 US US17/117,611 patent/US11058727B2/en active Active
- 2020-12-16 US US17/124,185 patent/US11103535B2/en active Active
-
2021
- 2021-01-15 US US17/150,257 patent/US11141437B2/en active Active
- 2021-01-15 US US17/150,110 patent/US11154576B2/en active Active
- 2021-01-22 US US17/155,933 patent/US11801264B2/en active Active
- 2021-01-22 US US17/155,960 patent/US11779606B2/en active Active
- 2021-01-22 US US17/155,468 patent/US11147838B2/en active Active
- 2021-01-22 US US17/155,494 patent/US11147839B2/en active Active
- 2021-04-05 CL CL2021000842A patent/CL2021000842A1/es unknown
- 2021-04-05 CL CL2021000841A patent/CL2021000841A1/es unknown
- 2021-04-13 US US17/229,411 patent/US11179418B2/en active Active
- 2021-04-13 US US17/229,447 patent/US11197892B2/en active Active
- 2021-07-02 US US17/366,894 patent/US11376281B2/en active Active
- 2021-07-16 US US17/377,735 patent/US11951132B2/en active Active
- 2021-07-16 US US17/377,724 patent/US11918607B2/en active Active
- 2021-09-10 US US17/472,293 patent/US11369636B2/en active Active
- 2021-09-17 US US17/478,036 patent/US11357797B2/en active Active
- 2021-12-08 JP JP2021199105A patent/JP7384884B2/ja active Active
-
2022
- 2022-04-14 AU AU2022202522A patent/AU2022202522B2/en active Active
- 2022-04-14 AU AU2022202520A patent/AU2022202520A1/en active Pending
- 2022-04-14 AU AU2022202512A patent/AU2022202512B2/en active Active
-
2023
- 2023-01-31 US US18/162,380 patent/US20230285460A1/en active Pending
- 2023-02-03 US US18/164,413 patent/US20230241109A1/en active Pending
- 2023-02-03 US US18/164,407 patent/US20230241108A1/en active Pending
- 2023-02-03 US US18/164,418 patent/US20230241110A1/en active Pending
- 2023-02-17 US US18/170,698 patent/US20230241113A1/en active Pending
- 2023-02-17 US US18/170,690 patent/US20230241112A1/en active Pending
- 2023-02-23 US US18/173,174 patent/US20230241114A1/en active Pending
- 2023-02-23 US US18/173,159 patent/US20230263830A1/en active Pending
- 2023-02-23 US US18/173,177 patent/US20230241115A1/en active Pending
- 2023-03-01 US US18/176,678 patent/US20230233612A1/en active Pending
- 2023-03-17 US US18/185,649 patent/US20230285461A1/en active Pending
- 2023-03-17 US US18/185,653 patent/US20230285462A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002387A1 (es) | Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123) | |
CL2020000983A1 (es) | Nuevo péptido de seq id no: 34 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819) | |
CL2020001897A1 (es) | Tratamientos contra el cáncer de útero. (divisional solicitud 201802508) | |
CL2021002459A1 (es) | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
CO2019012077A2 (es) | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer | |
CO2021004270A2 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
CL2021000225A1 (es) | Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados | |
CL2020002948A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878) | |
CO2021003404A2 (es) | Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados | |
CL2022003380A1 (es) | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) | |
CL2021000177A1 (es) | Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360) | |
CL2021001336A1 (es) | Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados | |
CL2020002935A1 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
CL2020002857A1 (es) | Nuevos péptidos (seq id no: 146) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096) | |
CL2021001012A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780) | |
CL2021001525A1 (es) | Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer (divisional de la solicitud no. 201803293) | |
AR115254A1 (es) | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer | |
AR114736A1 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados |